Cellebrite Faces Investigation over Q2 Miss and CEO Change
Kaplan Fox is probing Cellebrite for potential securities law violations following a significant quarterly earnings miss, a guidance cut, and an immediate CEO replacement.
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Cellebrite DI Ltd. (NASDAQ: CLBT) regarding possible securities law violations. The probe follows a series of adverse events in August 2026, including a missed revenue target, a reduction in full-year guidance, and the abrupt departure of the company's chief executive.
According to reports from GN stocks/nasdaq, the law firm is seeking information from investors who may have suffered financial losses during this period. The firm’s inquiry centers on whether management provided misleading information to the market before disclosing the operational challenges and leadership change that triggered a sharp decline in share value.
Quarterly Results Missed Internal Projections
On August 13, 2026, Cellebrite reported second-quarter total Annual Recurring Revenue of $507.8 million. This figure fell below the lower end of the company’s previously projected range of $510 million to $513 million. The shortfall indicates that the business failed to meet its own internal benchmarks for subscriber growth and contract value during the quarter.
Guidance Cut Amid Regulatory Delays
Concurrently with the earnings release, the company reduced its full-year annual recurring revenue guidance by approximately $15 million at the midpoint. Management attributed the downward revision to a foreign entity permit requirement applied to cloud technology, which delayed the closure of certain significant deals. This regulatory hurdle directly impacted the firm’s ability to convert pipeline opportunities into booked revenue.
Leadership Shift and Market Reaction
Cellebrite also announced an immediate change in top leadership, replacing CEO Tom Hogan with Shiv Ramji. The simultaneous announcement of the revenue miss, guidance cut, and CEO change resulted in a 29% drop in the stock price. Shares fell by $4.45 to close at $10.80 per share on August 13, reflecting a severe loss of investor confidence in the company’s near-term outlook.
